Janssen Pharmaceutica

Janssen to Exhibit Expanding Portfolio of Research at 2014 European Hematology Association (EHA) Annual Meeting

Beerse, Belgium (ots/PRNewswire) -

- Research in haematological malignancies features VELCADE(R), siltuximab,
  ibrutinib and daratumumab
- Note: This release corresponds to EHA abstracts S1345, P958, P957, P369, P353,
  P960, P1211, P1209, P461, P356, P350, P434, P109
 

Janssen Pharmaceutica NV announced data related to four compounds have been selected for presentation at the 19th European Hematology Association Congress (EHA) being held June 12-15, 2014 in Milan, Italy.

Data include VELCADE(R) (bortezomib), a first-in-class proteasome inhibitor to treat patients with multiple myeloma, which has also been investigated as a treatment for newly diagnosed patients with mantle cell lymphoma (MCL); siltuximab, an anti-interleukin-6 (IL-6) chimeric monoclonal antibody which recently received a positive CHMP opinion for the treatment of multicentric Castleman's disease (MCD). Data will also be presented for ibrutinib, an investigational compound which targets and blocks a specific protein (Bruton's tyrosine kinase) inhibiting cancer cell survival, in relapsed/refractory chronic lymphocytic leukaemia (CLL), MCL and other B-cell malignancies, and daratumumab, an investigational human CD38 monoclonal antibody being studied in multiple myeloma and other B-cell malignancies.

"Janssen has had a momentous year in haematology and has made signific